Another first – Rethymic approved for a Rare Pediatric Immune Disorder treatment
Rethymic, a regenerative tissue based therapy is now approved by the US FDA for patients with congenital athymia. It took more than 25 years for its research and development at the Duke University School of Medicine. Enzyvant acquired the license in 2017 and suffered FDA rejection in 2019. For many it was a surprise rejection,…
News ViewsMirum Pharma’s Livmarli (maralixibat) gets FDA nod to treat cholestatic pruritus
Livmarli is the first drug to be approved by the US FDA for the treatment of cholestatic pruritus in young patients with the super rare Alagille syndrome (ALGS). Developed by California based Mirum Pharmaceuticals, Maralixibat is an IBAT inhibitor that reduces the absorption of circulating bile acid levels. Its mechanism of action would ultimately lower…
Genzyme’s Nexviazyme gets US FDA Approval for Pompe disease treatment
Sanofi’s Genzyme has recently secured the FDA approval for Nexviazyme (avalglucosidasalfa-ngpt). It has received Breakthrough Therapy and Orphan Drug Designations. This willadd more scope for treating patients with late-onset Pompe disease, a rare genetic condition. Nexviazyme is the third innovative drug to be launched by Sanofi for the Pompe disease management. Myozyme and Lumizyme are…
Treating End-Stage Recurrent Glioblastoma with Oscillating Magnetic Field Therapy
Can a magnetic helmet treat cancerous tumors? A recent outcome from a human test of an investigational magnetic device indicates its possibility. In July 2021, a case report published in ‘Frontiers in Oncology’ confirms promising outcome of using an Oncomagnetic Device to treat Glioblastoma. It is an aggressive form of cancer that affects brain or…
AstraZeneca’s mAb Saphnelo scores FDA Approval for the treatment of Lupus
Systemic lupus erythematosus (SLE) is the most common type of Lupus, which is an autoimmune disease. Autoimmune disorders are not so rare, which are characterized by the immune system attacking own body tissues, affecting the vital organs. SLE can affect brain, lungs and kidneys along with joints, skin and blood vessels. The Lupus Foundation of…
Are they Harmful or Beneficial? Recent study outcomes of using Statins
The use of Statins has been a subject of worldwide debate among the medical professionals, especially the Cardiovascular Practitioners. Some physicians are even known for putting out notices mentioning they won’t prescribe Statins in their respective clinics. What makes them so controversial? If going by the side-effects, virtually every class of drugs comes with their…
AstraZeneca’s Tezepelumab found to significantly reduce Asthma Exacerbations
One of the global Biopharma Majors, AstraZeneca has recently announced that their Biologics License Application (BLA) for Tezepelumab has been granted Priority Review by the US FDA. This acceptance of Priority Review is for the treatment of Asthma. As per the company’s recent press release, Tezepelumab which is developed in collaboration with Amgen is the…
Antibiotics and Cancer? Understanding Antibiotics from the perspective of Cancer Risk
What causes Cancer? The ultimate causes of Cancer have been studied for decades and there doesn’t seem to be a single cause to isolate. Many conclusive studies point towards Genetics related to Hereditary and Lifestyle related to Alcohol and Tobacco, among the many causes or risk factors. Excess use or unguided use of Antibiotics is…
How Tata 1mg and Reliance’s Netmeds are changing India’s Retail Pharma Landscape?
For decades, the Indian Pharmaceutical distribution is driven by the Wholesale and Retail Pharma distributors and dealers. With the onset of Digital Pharma, this equation is expected to change. There will be no apprehension about the relevance of companies like 1mg and Netmeds. But, the impact of their success will be measured based on the…
Zydus Cadila in News for all the good reasons in recent times
Ranked fourth among the Indian Pharmaceutical companies, Zydus Cadila has been maintaining its reputation when it comes to offering innovative solutions. In times of Coronavirus pandemic, it has emerged as a front runner in terms of vaccine research and development. Simultaneously, the company has remained focused on strengthening its portfolio in other key segments. It…